BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27838121)

  • 1. Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
    Banerjee K; Ghosh RK; Kamatam S; Banerjee A; Gupta A
    Int J Cardiol; 2017 Jan; 227():556-564. PubMed ID: 27838121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
    Mihos CG; Krishna RK; Kherada N; Larrauri-Reyes M; Tolentino A; Santana O
    Pharmacol Res; 2016 Jan; 103():49-55. PubMed ID: 26546970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Anti-Anginal Drugs: Ranolazine.
    Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine: clinical applications and therapeutic basis.
    Hawwa N; Menon V
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):5-16. PubMed ID: 23335347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
    Yuriivna Osovska N; Vitaliivna Kuzminova N
    Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
    Ling H; Packard KA; Burns TL; Hilleman DE
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.
    Ghosh GC; Ghosh RK; Bandyopadhyay D; Chatterjee K; Aneja A
    Heart Views; 2018; 19(3):88-98. PubMed ID: 31007857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: an anti-anginal drug with further therapeutic potential.
    Reffelmann T; Kloner RA
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population.
    Lisi D; Andrews E; Parry C; Hill C; Ombengi D; Ling H
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):755-761. PubMed ID: 31802311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
    Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
    Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on evidence for treatment with ranolazine in stable angina.
    Carbone F; Montecucco F; Mach F
    Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of ranolazine in the patient with microvascular angina, atrial fibrillation and migraine.
    Osovska NY; Kuzminova NV
    Wiad Lek; 2016; 69(6):832-837. PubMed ID: 28214825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
    Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
    Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ranolazine in the prevention and treatment of postoperative atrial fibrillation in patients undergoing cardiac surgery.
    Tsu LV; Lee S
    Ann Pharmacother; 2014 May; 48(5):633-7. PubMed ID: 24523397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
    Scirica BM; Belardinelli L; Chaitman BR; Waks JW; Volo S; Karwatowska-Prokopczuk E; Murphy SA; Cheng ML; Braunwald E; Morrow DA
    Europace; 2015 Jan; 17(1):32-7. PubMed ID: 25210025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine (Ranexa) for chronic stable angina.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.